Moleculin Biotech (MBRX) Accounts Payables (2015 - 2026)
Moleculin Biotech (MBRX) posted quarterly Accounts Payables of $3.5 million for Q4 2025, up 72.81% year-over-year from $2.0 million in Q4 2024, and up 65.78% quarter-over-quarter from $2.1 million in Q3 2025.
Moleculin Biotech (MBRX) Accounts Payables (2015 - 2026) Analysis & Trends
Moleculin Biotech's Accounts Payables history runs 11 years deep, the most recent figure standing at $3.5 million for Q4 2025.
- In Q4 2025, Accounts Payables rose 72.81% year-over-year to $3.5 million; the TTM figure through Dec 2025 stood at $3.5 million (up 72.81% YoY), while the FY2025 annual figure was $3.5 million, up 72.81% from the prior year.
- Accounts Payables for Q4 2025 stood at $3.5 million, up from $2.1 million in the prior quarter.
- The five-year high for Accounts Payables was $4.1 million in Q2 2023, with the low at $1.4 million in Q4 2021.
- The 5-year median for Accounts Payables is $2.2 million (2022), against an average of $2.5 million.
- The sharpest annual moves came in 2022 and 2023: Accounts Payables surged 156.69% in 2022, then sank 43.72% in 2023.
- Moleculin Biotech's Accounts Payables stood at $1.4 million in 2021, then surged by 53.59% to $2.1 million in 2022, then advanced by 19.24% to $2.5 million in 2023, then decreased by 18.73% to $2.0 million in 2024, then soared by 72.81% to $3.5 million in 2025.
- Business Quant data shows MBRX's Accounts Payables at $3.5 million in Q4 2025, $2.1 million in Q3 2025, and $3.7 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.92 Bn | 131.07 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.91 Bn | 77.91 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.87 Bn | 59.68 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.18 Bn | 53.04 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.96 Bn | 36.87 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.53 Bn | 28.23 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 27.79 Bn | 9.40 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.37 Bn | 26.53 Bn | - | 35.57 Mn |
| 10 | Moleculin Biotech | 3.30 Mn | 3.30 Mn | - | 4.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.34 Mn |
| Dec 31, 2025 | 3.51 Mn |
| Sep 30, 2025 | 2.12 Mn |
| Jun 30, 2025 | 3.72 Mn |
| Mar 31, 2025 | 2.71 Mn |
| Dec 31, 2024 | 2.03 Mn |
| Sep 30, 2024 | 2.55 Mn |
| Jun 30, 2024 | 2.83 Mn |
| Mar 31, 2024 | 2.10 Mn |
| Dec 31, 2023 | 2.50 Mn |
| Sep 30, 2023 | 2.01 Mn |
| Jun 30, 2023 | 4.14 Mn |
| Mar 31, 2023 | 1.94 Mn |
| Dec 31, 2022 | 2.10 Mn |
| Sep 30, 2022 | 3.57 Mn |
| Jun 30, 2022 | 3.18 Mn |
| Mar 31, 2022 | 2.22 Mn |
| Dec 31, 2021 | 1.36 Mn |
| Sep 30, 2021 | 1.39 Mn |
| Jun 30, 2021 | 1.51 Mn |